Eli Lilly Suspends COVID-19 Antibody Therapy Trial Over “Potential Safety Concern”
Tue, 10/13/2020 – 14:41
Barely a week after applying for emergency use approval from the FDA for one of its COVID-19 antibody therapeutics, it appears trials for one of Eli Lilly’s therapeutic drugs focused on the virus (Eli Lilly is working on more than just one) have been paused, according to an NYT report.
Per the NYT report, the government-sponsored clinical trial has been paused because of a “potential safety concern.” The report cited emails that government officials sent on Tuesday to researchers at testing sites, which the company confirmed. The trial was designed to test the benefits of the therapy on hundreds of people already infected with the virus. The company did not say how many volunteers were sick, or any details about their illness.
This comes after Johnson & Johnson confirmed that it had voluntarily paused its Phase 3 vaccine trials after a participant in the 60k person trial came down with an unusual and unspecified illness. An AstraZeneca trial in the US has still not restarted.
ELI LILLY ANTIBODY TRIAL IS PAUSED BECAUSE OF POTENTIAL SAFETY- NYT REPORTER pic.twitter.com/w70hWf8D5I
— Quoth the Raven (@QTRResearch) October 13, 2020
As we noted last night, convincing the public to trust the vaccines is critically important, according to a team of analysts at Goldman Sachs, who recently warned that convincing the public to accept the vaccine is an understated risk.
Stocks tumbled on the news.
Join our Telegram channels
- All Headlines: t.me/LiquidaryNewsRoom
- Finance Headlines: t.me/LiquidaryFinance
- Liquidary Insiders: t.me/LiquidaryInsiders
- Crypto Headlines: t.me/LiquidaryCrypto
- Politics Headlines: t.me/LiquidaryPolitics
Join our Telegram group ➡️ t.me/Liquidary
Follow us Twitter ➡️ twitter.com/liquidary
Find the full article here